Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Netarsudil for open-angle glaucoma or ocular hypertension. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Glaucoma is a serious condition caused by abnormal pressure within the eye leading to blindness. All glaucoma treatments aim to prevent further damage to sight, but any damage to vision that has already been caused by glaucoma cannot be repaired. Glaucoma can be treated with eye drops, tablets, laser surgery, eye surgery or a combination of these methods.
Netarsudil is a new eye drop to treat patients with glaucoma. It works by reducing the pressure and increasing fluid removal from the eye to prevent further damage to the eye. Netarsudil is taken as an eye drop once a day.
If licensed for use in the UK, it could be a new treatment option for patients with glaucoma which works differently compared to other glaucoma eye drops. Indexing Status Subject indexing assigned by CRD MeSH Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000644 Date abstract record published 19/04/2016 |